{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Neutropenic Fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment Delay"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Determined the number of participants who had either a fever due to abnormally low level of neutrophils, a type of white blood cell, on the day of study drug treatment, or the participants who had the study drug treatment delayed due to an abnormally low level of neutrophils.","groups":[{"description":"Paclitaxel 135 mg/m\\^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m\\^2 IV over 90 minutes; Doxorubicin 40 mg/m\\^2 IV over 20 minutes; treatment may repeat every 2 weeks for up to nine courses. Subcutaneous Injection of Pegfilgrastim on day 1 or 2 of each course, after chemotherapy.","id":"OG000","title":"Gemcitabine, Paclitaxel and Doxorubicin"}],"paramType":"NUMBER","populationDescription":"Thirty-two patients (82%) received Pegfilgrastim immediately after chemotherapy on day 1 of the cycle.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Safety and Efficacy of Same-day Pegfilgrastim","type":"SECONDARY","unitOfMeasure":"participants"}